# Case Report: Novel GLA mutation in a Chinese female with renal-predominant Fabry disease and cardiac hypertrophy

## TL;DR

A 72-year-old Chinese woman with kidney failure and heart issues was found to have a new GLA gene mutation causing Fabry disease, highlighting the need for genetic testing in atypical cases.

## Contribution

The paper reports the first documented case of the novel GLA c.522T>G (p.Cys174Trp) mutation in East Asians with Fabry disease.

## Key findings

- The GLA c.522T>G (p.Cys174Trp) variant was identified as likely pathogenic in a patient with renal and cardiac manifestations.
- Family members carrying the variant showed reduced α-Gal A activity and elevated lyso-Gb3 levels.
- The case expands the mutational spectrum of Fabry disease in East Asian populations.

## Abstract

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by GLA gene mutations, leading to deficient α-galactosidase A (α-Gal A) activity and progressive accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) in multiple tissues. Diagnosis remains challenging in late-onset renal-predominant phenotypes.

A 72-year-old Chinese female presented with end-stage renal disease (ESRD) and hypertrophic cardiomyopathy, prompting a clinical suspicion of FD. The diagnosis was confirmed by the identification of a novel GLA missense variant, c.522T>G (p.Cys174Trp), which was classified as likely pathogenic. All tested family members who carried this variant exhibited the characteristic biochemical phenotype of reduced α-Gal A activity and elevated lyso-Gb3 levels.

This report describes the first documented case of the GLA c.522T>G (p.Cys174Trp) variant, expanding the mutational spectrum of FD in East Asians. The coexistence of ESRD and cardiac hypertrophy should prompt clinicians to consider GLA screening, particularly in females with atypical presentations.